EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the “Undruggable” Paradigm

Wenyu Li, Xiang Lin, Pan Liu, Jing Zhang, Chuanjiang Liu

Turkish Journal of Gastroenterology · 2026

DOI: 10.5152/tjg.2026.25595 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Turkish Journal of Gastroenterology, 2026. Verfasst von Wenyu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic Surgery, People's Hospital of Henan University/Zhengzhou University People's Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies, exhibits a 5-year survival rate below 10% and extremely poor clinical prognosis. Over 90% of PDAC patients harbor KRAS gene driver mutations, which promote tumor proliferation, invasion, and immunosuppression of the tumor microenvironment through constitutive activation of downstream RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways. Although the therapeutic potential of targeting KRAS has been recognized for decades, its smooth protein structure and lack of traditional drug-binding pockets led to its long-standing classification as an “undruggable” target, resulting in limited efficacy of early targeted agents. Recent breakthroughs with next-generation KRAS inhibitors have transformed the therapeutic landscape for pancreatic cancer. This review synthesizes evidence from basic research and clinical translation to provide a theoretical foundation and practical guidance for the precision treatment of KRAS-mutant pancreatic cancer.Cite this article as: Li W, Lin X, Liu P, et al. Emerging therapeutic landscapes for KRAS-mutant pancreatic ductal adenocarcinoma: beyond the “undruggable” paradigm. Turk J Gastroenterol. Published online January 30, 2026. doi: 10.5152/tjg.2026.25595

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)MutationHumansSignal TransductionMolecular Targeted TherapyTumor MicroenvironmentAntineoplastic Agents

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hepato-Biliary-Pancreatic Surgery, People's Hospital of Henan University/Zhengzhou University People's Hospital, Zhengzhou, China.

Zitieren

APA

Li, W., Lin, X., Liu, P., Zhang, J., & Liu, C. (2026). Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the “Undruggable” Paradigm. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2026.25595

Vancouver

Li W, Lin X, Liu P, Zhang J, Liu C. Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the “Undruggable” Paradigm. Turkish Journal of Gastroenterology. 2026. doi:10.5152/tjg.2026.25595

BibTeX
@article{Li2026,
  author = {Li, Wenyu and Lin, Xiang and Liu, Pan and Zhang, Jing and Liu, Chuanjiang},
  title = {Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the “Undruggable” Paradigm},
  journal = {Turkish Journal of Gastroenterology},
  year = {2026},
  doi = {10.5152/tjg.2026.25595}
}
Kostenlos starten →